For the year ending 2025-12-31, PROF had $2,689K increase in cash & cash equivalents over the period. -$38,383K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss for the year | -42,570 |
| Depreciation of property and equipment (note 5) | 373 |
| Amortization of intangible assets (note 6) | 187 |
| Non-cash lease expense adjustment | 37 |
| Share-based compensation (note 11) | 5,490 |
| Interest and accretion expense (note 8) | 63 |
| Trade and other receivables (note 3) | 172 |
| Inventory (note 4) | 2,822 |
| Prepaid expenses and deposits | -464 |
| Accounts payable, accrued expenses and other liabilities (note 7) | 378 |
| Deferred revenue | 371 |
| Income taxes payable (note 13) | 42 |
| Deferred tax assets (note 13) | -26 |
| Net cash used in operating activities | -38,207 |
| Purchase of property and equipment (note 5) | 176 |
| Purchase of intangible assets (note 6) | 66 |
| Net cash used in investing activities | -242 |
| Issuance of commons shares (note 10) | 42,436 |
| Payments of financing costs (note 10) | 1,016 |
| Repayments of long-term debt (note 8) | 290 |
| Proceeds from the exercise of stock options (note 11) | 8 |
| Net cash provided by financing activities | 41,138 |
| Net increase in cash and cash equivalents | 2,689 |
| Effect of exchange rate changes on cash | 2,122 |
| Cash, beginning of year | 54,912 |
| Cash, end of year | 59,723 |
Profound Medical Corp. (PROF)
Profound Medical Corp. (PROF)